However, if APOE genotype is an important modifier of the effect, then studies involving human patients will need to account for APOE genotype to determine who is at risk for endotoxemia-induced dementia, and to plan for appropriate sample sizes for population-based studies. This evidence concerns the gene APOE and dementia.